NCT04975737View on ClinicalTrials.gov

Study of the Safety and Efficacy of the Subunit Recombinant Tuberculosis Vaccine GamTBvac

PHASE3RecruitingINTERVENTIONAL
Enrollment

7,180

Participants

Timeline

Start Date

January 20, 2022

Primary Completion Date

November 30, 2025

Study Completion Date

November 30, 2025

Conditions
Tuberculosis
Interventions
BIOLOGICAL

GamTBvac

The subunit recombinant tuberculosis vaccine GamTBvac (lyophilisate for preparation of solution for subcutaneous administration, 5.35 mg / dose)

BIOLOGICAL

Placebo

Placebo for subcutaneous administration

Trial Locations (1)

197706

RECRUITING

City hospital #40, Saint Petersburg

All Listed Sponsors
lead

Gamaleya Research Institute of Epidemiology and Microbiology, Health Ministry of the Russian Federation

OTHER